Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Astex Pharmaecuticals, Inc and Bristol Myers Squibb.

Providing Patient-Centric Care in MDS and MPNs: Improving Outcomes and Quality of Life With New Therapeutic Options

Release Date: June 17, 2021
Expiration Date: June 17, 2022

Activity Overview

This online, on-demand virtual program brings together expert faculty to discuss the treatment of myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPNs). Treatment of these conditions depends on careful diagnosis, risk stratification, and management approaches to reduce symptom burden and risk of complications. Novel treatment options offer the chance to improve disease control, but their optimal use relies on careful consideration of disease and patient features.

These discussions will be reinforced using case presentations highlighting current challenges in the clinic, as well as potential treatment options for these patients in the near future. The overall goal of this program is to help participants make informed treatment decisions for patients with MDS and MPNs, while managing the treatment- and disease-related complications that may arise from these malignancies.

This educational activity is an archive of the live virtual presentation held on June 7, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Astex Pharmaecuticals, Inc and Bristol Myers Squibb.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the clinical criteria for MDS and MPN diagnosis, and methods for risk stratification
  • Determine the impact of risk stratification on therapy decision-making for patients with MDS and MPNs
  • Summarize clinical trial evidence on evolving treatment strategies for low- to intermediate-risk MDS, MPNs, and associated anemia
  • Apply evidence from landmark trials evaluating emerging therapies in MDS and MPNs to real-world case scenarios in the management of patients with these diseases

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Ruben A. Mesa, MD, FACP
Ruben A. Mesa, MD, FACP
Executive Director and Professor of Medicine
Mays Family Foundation Distinguished University Presidential Chair
Mays Cancer Center
UT Health San Antonio MD Anderson Cancer Center
San Antonio, TX

Disclosures: Grant Research Support: Incyte, Gilead, CTI, Celgene, Abbvie, Genentech; Consultant: AOP Orphan, La Jolla Pharmaceuticals, Novartis, Sierra Oncology.

Prithviraj Bose, MD
Prithviraj Bose, MD
Associate Professor Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Astellas, Blueprint Medicines, Celgene/Bristol Myers Squibb, Constellation Pharmaceuticals, CTI BioPharma, Incyte, Kartos Therapeutics, NS Pharma, Pfizer, Promedior; Consultant: Blueprint Medicines, Celgene/Bristol Myers Squibb, CTI BioPharma, Kartos Therapeutics, Novartis, Sierra Oncology.

Rami S. Komrokji, MD
Rami S. Komrokji, MD
Senior Member
Section Head - Leukemia & MDS
Vice Chair - Department of Malignant Hematology
Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida
Tampa, FL

Disclosures: Consultant: AbbVie, Agios Pharmaceutical, Celgene/Bristol Myers Squibb, Geron, Jazz Pharmaceuticals, Novartis; Speakers Bureau: AbbVie, Agios Pharmaceuticals, Celgene/Bristol Myers Squibb, Jazz Pharmaceuticals.

David Sallman, MD
David Sallman, MD
Assistant Member
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, FL

Disclosures: Grant/Research Support: Celgene, Jazz; Consultant: AbbVie, Agios Pharmaceuticals, Aprea Therapeutics, Bristol Myers Squibb, Celyad Oncology, Gilead Sciences, Intellia Therapeutics, Kite Therapeutics, Magenta Therapeutics, Novartis, Shattuck Labs, Syndax Pharmaceuticals; Speakers Bureau: Agios Pharmaceuticals, Bristol Myers Squibb, Incyte.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By